nabilone
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
80
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Neuropathic Pain
Conditions
Neuropathic Pain, Multiple Sclerosis
Trial Timeline
Jun 1, 2007 โ Jul 1, 2012
NCT ID
NCT00480181About nabilone
nabilone is a approved stage product being developed by Bausch Health for Neuropathic Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT00480181. Target conditions include Neuropathic Pain, Multiple Sclerosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00480181 | Approved | Completed |
| NCT00384410 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Neuropathic Pain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CHF6467 active | Comac Medical | Phase 1/2 | 33 |
| LY3857210 + Placebo | Eli Lilly | Phase 2 | 52 |
| OK-101 0.05% + OK-101 0.1% + Placebo | OKYO Pharma | Phase 2 | 44 |
| YHD1119 + Lyrica | Yuhan | Phase 3 | 77 |
| YHD1119 300mg + YHD1119 300mg | Yuhan | Phase 1 | 33 |
| pregabalin sustained release tablet + pregabalin immediate release capsule | Yuhan | Approved | 85 |
| DS-5565 + placebo | Daiichi Sankyo | Phase 3 | 77 |
| Mirogabalin + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| DS-1971a + placebo + pregabalin | Daiichi Sankyo | Phase 2 | 52 |
| DS-5565 | Daiichi Sankyo | Phase 3 | 77 |
| Placebo + Mirogabalin | Daiichi Sankyo | Phase 3 | 77 |
| Qutenza | Astellas Pharma | Pre-clinical | 23 |
| Qutenza exposure | Astellas Pharma | Pre-clinical | 23 |
| Duloxetine + Pregabalin + Placebo | Shionogi | Approved | 85 |
| LY3016859 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY4065967 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY3848575 + Placebo | Eli Lilly | Phase 2 | 52 |
| ABT-639 + pregabalin + Placebo | AbbVie | Phase 2 | 52 |